MacroGenics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell MacroGenics and other ETFs, options, and stocks.About MGNX
MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases.
CEOEric Risser
CEOEric Risser
Employees341
Employees341
HeadquartersRockville, Maryland
HeadquartersRockville, Maryland
Founded2000
Founded2000
Employees341
Employees341
MGNX Key Statistics
Market cap102.29M
Market cap102.29M
Price-Earnings ratio-1.33
Price-Earnings ratio-1.33
Dividend yield—
Dividend yield—
Average volume2.50M
Average volume2.50M
High today$1.68
High today$1.68
Low today$1.57
Low today$1.57
Open price$1.62
Open price$1.62
Volume444.16K
Volume444.16K
52 Week high$3.60
52 Week high$3.60
52 Week low$0.9897
52 Week low$0.9897
Stock Snapshot
As of today, MacroGenics(MGNX) shares are valued at $1.61. The company's market cap stands at 102.29M, with a P/E ratio of -1.33.
As of 2025-12-29, MacroGenics(MGNX) stock has fluctuated between $1.57 and $1.68. The current price stands at $1.61, placing the stock +2.5% above today's low and -4.2% off the high.
MacroGenics(MGNX) shares are trading with a volume of 444.16K, against a daily average of 2.5M.
During the past year, MacroGenics(MGNX) stock moved between $0.99 at its lowest and $3.60 at its peak.
During the past year, MacroGenics(MGNX) stock moved between $0.99 at its lowest and $3.60 at its peak.
Analyst ratings
57%
of 7 ratingsBuy
42.9%
Hold
57.1%
Sell
0%
People also own
Based on the portfolios of people who own MGNX. This list is generated using Robinhood data, and it’s not a recommendation.